Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Equity Ratio (2016 - 2025)

VYNE Therapeutics' Equity Ratio history spans 10 years, with the latest figure at 0.92 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 18.25% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, up 18.25%, while the annual FY2025 figure was 0.92, 18.25% up from the prior year.
  • Equity Ratio reached 0.92 in Q4 2025 per VYNE's latest filing, up from 0.87 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q4 2025 to a low of 0.56 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2025.
  • Peak YoY movement for Equity Ratio: soared 81.37% in 2021, then tumbled 30.09% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then increased by 5.53% to 0.77 in 2022, then rose by 18.66% to 0.91 in 2023, then dropped by 14.3% to 0.78 in 2024, then increased by 18.25% to 0.92 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Equity Ratio are 0.92 (Q4 2025), 0.87 (Q2 2025), and 0.78 (Q1 2025).